Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

ZYN002 shows promise in rat models of addiction
May 2018
SHARING OPTIONS:

DEVON, Pa.—Clinical-stage pharmaceutical company Zynerba Pharmaceuticals Inc. recently announced that scientists from The Scripps Research Institute and the University of Maryland have produced preclinical data from an NIH-funded study potentially supporting the use of ZYN002—transdermal cannabidiol (CBD)—to reduce the risk of relapse in recovering drug and alcohol addicts. ZYN002 is the first and only pharmaceutically produced CBD formulated as a permeation-enhanced transdermal gel. The researchers state in a Neuropsychopharmacology paper that the study findings provide proof of principle supporting ZYN002’s ability to prevent relapse due to “beneficial actions across several vulnerability states and long-lasting effects with only brief treatment,” as noted in a press release. Transdermal delivery was found to produce stable, sustained plasma CBD levels in a rat model of drug addiction, and found that even five months after therapy, ZYN002-treated rats had reduced relapse caused by stress or drug cues.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.